Clinical Trial Update: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating aprepitant to prevent nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Extrahepatic Bile Duct Cancer, Nausea | Phase 2 | Status: COMPLETED | Results posted: 2012-10-30